<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082069</url>
  </required_header>
  <id_info>
    <org_study_id>NMRC 2003.0006</org_study_id>
    <secondary_id>WRAIR 1085</secondary_id>
    <secondary_id>HSRRB A-12528</secondary_id>
    <nct_id>NCT00082069</nct_id>
  </id_info>
  <brief_title>Invaplex 50 Vaccine Dose-Ranging</brief_title>
  <official_title>Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <brief_summary>
    <textblock>
      The vaccine is given as a nose spray. Volunteers will receive a 3-dose vaccination with doses&#xD;
      spaced two weeks apart. Volunteers will be assigned to a vaccination group based on their&#xD;
      order of enrollment with consideration of their availability to complete the necessary&#xD;
      vaccinations and follow-up visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-labeled dose escalating trial in which a total of 32 subjects (minimum of 24&#xD;
      allowable) will receive one of four intranasal Invaplex 50 vaccine doses according to the&#xD;
      following chart:&#xD;
&#xD;
      Test articles/dose&#xD;
&#xD;
      Group / N* / Invaplex 50&#xD;
&#xD;
      A / 8 / 10 micrograms&#xD;
&#xD;
      B / 8 / 50 micrograms&#xD;
&#xD;
      C / 8 / 240 micrograms&#xD;
&#xD;
      D / 8 / 480 micrograms&#xD;
&#xD;
      *minimum of 6 volunteers/group&#xD;
&#xD;
      An interval no less than 7 days following the third (and final) dose (total of 35 days&#xD;
      between initial dose at the lower dose level and the next initial dose at the next higher&#xD;
      dose level) will separate volunteer groups receiving different doses. All volunteers will&#xD;
      receive three immunizations. The first dosing time point is Day 0, the second is Day 14 (+-&#xD;
      one day), and the third is Day 28 (+- 2 days). Blood and stool specimens will be collected at&#xD;
      intervals to examine systemic and mucosal vaccine antigen-specific immune responses. Vaccine&#xD;
      safety will be actively monitored during vaccination and for 28 days following the third&#xD;
      vaccination dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mucosal immune response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic immune response</measure>
  </primary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Diarrhea</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shigella flexneri 2a Invaplex 50</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be in very good health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker, or have stopped smoking less than one year ago&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  History of chronic illnesses, such as: asthma, chronic sinusitis, or chronic seasonal&#xD;
             allergies (such as hay fever)&#xD;
&#xD;
          -  Received a vaccination for Shigella or exposure to Shigella bacteria in a research&#xD;
             study or through work in a laboratory&#xD;
&#xD;
          -  Positive for HIV, hepatitis B, and hepatitis C by blood test&#xD;
&#xD;
          -  Using anti-diarrheal, anti-constipation, or antacid medications on a regular basis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tribble, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naval Medical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 28, 2004</study_first_submitted>
  <study_first_submitted_qc>April 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2004</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shigella</keyword>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

